Member Info for Moneymunch

Agreed Porter, the Hevolution Foundation, the Saudi organisation who have an annual $1 billion dollar investment fund into the longevity space, who appear to have close links to Eirc Verdin, a highly respected and leading scientist who sits on Genflow’s Scientific Advisory Board. Hevolution invested $20m into the Buck Institute end of 2023, where Eric Verdin is the CEO and invested a further $20m 2024 into Aeovian, who just so happen to be founded by the Buck Institute. Gl :-)

No XPrize, but still a huge vote of confidence from the Saudi's with yesterdays TR1 for 4.45%, as well as 2.6% from the Aberdeen Group and the £0.5m subscription from a US Longeity Fund, all bodes well for a stellar period ahead!!! Gla ;-)

Lol Northeast and every chance Porter. Genflow and Sirt6's panacea potential certainly meet the XPrize criteria;

The aim of the seven-year XPrize Healthspan is to develop a way for humans to dramatically rejuvenate muscles, cognition and immune functions, the three systems crucial to healthy ageing.

We know the potential therapeutic benefits of Sirt6 over immune functions and Genflow's collaboration with Revatis for Sarcopenia;

· Sarcopenia research program with Revatis SA - focusing on the development of muscle progenitor cells loaded with Genflow's proprietary SIRT6, for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function.

and also very interesting and perhaps timely was Genflow's LinkedIn post a couple of weeks ago;

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,929 followers

1w

Can We Delay Cognitive Aging?

#Neurodegeneration is one of aging’s biggest challenges - memory loss, confusion, and diseases like #Alzheimer’s take a toll on quality of life.

Our research at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) focuses on #longevity genes that could help protect brain function, keeping minds sharper for longer.

#GENF #GENFF #Aging #BrainFunction

and then if that wasn't enough, we get a TR1 from a high profile and influential Saudi taking 4.5%, and of course the XPRIZE is funded by he Saudis via the Hevolution Group. Could be pie in the sky but we'll find out tonight and/or definitely 7am tomorrow morning. In the meantime regardless, Genflow is about to embark on a stellar run, just as long good news keeps rolling in. Excitement building!!! Gl :-)

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest milestone—a successful £0.5 million fundraising to support a gene therapy trial in ageing dogs using SIRT6.

Dr Leire explained that the funding was secured via a share subscription from a US-based longevity fund, with shares issued at market price and without a discount—what he described as a clear “vote of confidence in the company and its therapies.”

The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. “It worked like magic in mice. We reasonably think that it will work likewise in dogs,” Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies.

Leire also highlighted the commercial potential of targeting animal health, as it offers a shorter regulatory pathway compared to human applications. He confirmed that the trial has reached a key milestone: the randomisation of 24 senior dogs, aged over ten years, into four arms, including one control group and three treatment groups using different SIRT6 delivery methods.

He also addressed ethical considerations, stating that the therapy does not involve genetic modification, and described the use of non-integrating gene therapy approaches, including naked DNA and AAV vectors.

Incredible news Northeast, and not many more high profile . Question is, has he declared his hand before the XPRIZE finalist announcement, 6pm ET, which is 11pm UK time tonight. Fingers crossed for a stellar RNS 7am tomorrow!!!😁😎🤞🤞🤞

Wow wow, a high profile Saudi who must have great knowledge of the Saudi backed Hevolution Foundation and XPrize!!!??? Gla :-)

We’re bringing the biggest healthspan innovation event of the year to your screens. Find out who the #XPRIZEHealthspan Semifinalists and FSHD Bonus Prize Finalists are during our livestream on May 12 starting at 6pm ET / 3pm PT. Register: https://whova.com/portal/registration/NJehdnzcoBEWAH3R1gGo/3msbzwev

Wow, and has just taken 4.45% share holding in Genflow!!! Gla :-)

The aim of the seven-year XPrize Healthspan is to develop a way for humans to dramatically rejuvenate muscles, cognition and immune functions, the three systems crucial to healthy ageing.

The winning team should be able to restore these three systems by a minimum of 10 – but ideally 20.

Given Sirt6's panacea potential across multiple disease targets and XPrize Healthspan criteria, one would have thougt Genflow could be in the running. Gla ;-)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,929 followers

6d

💪 Muscle Loss & #Aging – Can We Stop It?

📉 After age 30, we lose 3-8% of muscle mass per decade, leading to frailty and loss of independence. Current solutions focus on exercise and nutrition, but #biotech could offer more.

🧬 At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we’re investigating how gene therapy could help maintain #muscle strength and delay #age related decline. A stronger future starts with science.

#HealthyAging #Longevity #GENF #GENFF

..........

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,929 followers

1w

Can We Delay Cognitive Aging?

#Neurodegeneration is one of aging’s biggest challenges - memory loss, confusion, and diseases like #Alzheimer’s take a toll on quality of life.

Our research at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) focuses on #longevity genes that could help protect brain function, keeping minds sharper for longer.

#GENF #GENFF #Aging #BrainFunction

...........

SIRT6, a sirtuin protein, plays a complex and multifaceted role in immune functions, acting as both a regulator and an inhibitor of inflammation, and influencing various aspects of immune cell behavior. It impacts immune cell metabolism, T cell differentiation, and the balance of immune cell populations, demonstrating its influence on both innate and adaptive immunity.

Ageing

$101m longevity research prize aims to ‘shatter the limits’ on ageing

Teams vie for place on shortlist for XPrize Healthspan, the richest prize yet in the longevity field

Sun 11 May 2025 15.37 BST

Admitting its goal is “audacious”, the largest longevity-focused prize in history – offering $101m (£76m) in prize money – will announce its shortlist of candidates on Monday.

The aim of the seven-year XPrize Healthspan is to develop a way for humans to dramatically rejuvenate muscles, cognition and immune functions, the three systems crucial to healthy ageing.

“This competition isn’t just accelerating progress, it’s shattering the limits of what’s possible when it comes to ageing,” said Jamie Justice, the executive director of XPrize, run by the XPrize Foundation and backed by funders including the Hevolution Foundation.

The winning team should be able to restore these three systems by a minimum of 10 – but ideally 20 – years in humans aged 50 to 80. A key condition of the final prize is that the innovation is accessible to as many people as cheaply and easily as possible.

Another condition is that there will be no delay in rolling out the solution: the winning idea must be scalable in 12 months or less of the final award being made in 2030, after a final $81m one-year clinical trial in older adults.

.....

On Monday, the biggest prize in the longevity field comes closer as 40 semi-finalist teams are pulled from the XPrize longlist, which comprised more than 1,000 scientists, clinicians, biomedical engineers, longevity technology leaders, pharmaceutical companies, students, biohacker groups and newcomers to the field.

These teams – 14 of which come from the UK – have suggested a wide range of innovations including pharmacological approaches, biological therapies and lifestyle-based interventions, and often combinations of all three.

htTps://www.theguardian.com/science/2025/may/11/101m-xprize-healthspan-longevity-research-prize-ageing

Yep, and also Friday's £.5m subscription, which would be known to the £435k Institutional Investor will no doubt have delayed all TR1's in the pipeline until the final share figure of number of shares are confirmed. Also , news of the Aberdeen Group's 2.6% share investment could be part of the share equity investment....All in the mix regardless, and now a very exciting period ahead from a fully funded Genflow. Gl :-)

Eric did say in his interview with Proactive Investor's after the announcement, the investment was bringinh in credible investors from outside the UK, including the US , and so perhaps the Institutional Investor is representing several investors who have participated , but all under the 3% reporting threshold, and so collectively no TR1 is required.??? Although, with another 41m shares in issue, the % holding of Genflow's existing major shareholders might require a TR1 or two .

Although somewhat orchestrated, especially from those in the know, and no doubt encouraged many pi's to sell at a significant loss as the sp slid to the 0.8p subscription price. Genflow have just received almost £1m cash in the bank over the last week or so and have €4.7m non-dilutive grant cash outstanding and a lowly £3.5m market cap. Shouldn't be too long before this re-rates significantly as Eric delivers material news on the pipeline in the coming weeks on multiple fronts!!! Gla ....On and UP!!! :-)

8th May 2025

Top Trump admin health officials share vision for HHS to 'Make America Healthy Again'

'Special Report' spoke with officials from the FDA, NIH and CMS Fox News

Four top Trump administration officials from the United States Department of Health and Human Services (HHS) shared their visions for improving the American healthcare system and aligning the agency with the "Make America Healthy Again" (MAHA) platform in an exclusive interview Thursday on "Special Report."

HHS Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, Food and Drug Administration (FDA) Commissioner Dr. Marty Makary and National Institutes of Health director Dr. Jay Bhattacharya sat down with Fox News chief political anchor Bret Baier at the Hubert H. Humphrey Building in Washington, D.C., for a wide-ranging discussion on the future of healthcare and improving the quality of care nationwide.

......

Drs. Bhattacharya, Makary and Oz said their goals at their respective agencies are to: improve the health and LONGEVITY of the American people, focus on cures and meaningful treatments and improve the quality of care on all levels.

htTps://www.foxnews.com/media/top-trump-admin-health-officials-share-vision-hhs-make-america-healthy-again

0

Another £500k cash in the bank along with the £435k cash a week or so ago. More cash expected from the €4m non-dilutive grant funding approved October 2024 and the £700k outstanding from the £1.5m grant April 2024, and plenty more potential material news at anytime. Hopefully we should see a recovery in sp in the coming days and weeks as the dust settles on the admission of the new shares. Gla:-)

Total Voting Rights

Application will be made for the 62,500,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 15 May 2025 (the "Admission").

Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 453,547,942.

The above figure of 453,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Clinical Progress of Canine Longevity Trial

Coinciding with the fundraise, Genflow reached a key milestone with the randomization of 24 senior dogs enrolled in its ongoing proof-of-concept clinical trial.

Delivered via intravenous injection, the therapy targets cellular energy metabolism and longevity pathways. Genflow and its partners are conducting the study in accordance with the rigorous scientific protocols, leading animal welfare practices, and a committement to innovation.

The study is designed to evaluate the potential of Genflow's SIRT6 gene therapy to improve muscle function, reduce biological markers of aging, and support overall vitality in senior dogs, potentially uncovering insights that could help extend the quality of life for humans. An overview can be seen below:

· Participants: 24 senior dogs (male and female), aged 10+ years

· Design: Randomized, controlled, dose-escalation trial

· Endpoints: Safety of the gene therapy, Muscle strength and mass, biological age estimation (via pan-mammelian methylation clocks), and overall health indicators

The Company will keep the market informed of future developments as trials proceed.

Eric Leire, CEO of Genflow, commented:

"This investment, without applying any discount, is a strong vote of confidence in our science and our mission to improve aging through innovative biotechnology. With this support, we are well-positioned to accelerate our research and bring us closer to delivering impactful solutions to patients."

hTtps://www.londonstockexchange.com/news-article/GENF/share-subscription-director-s-dealing-and-update/17027661

RNS Number : 9758H

Genflow Biosciences PLC

09 May 2025

9 May 2025

Genflow Biosciences plc

("Genflow" or the "Company")

Genflow Secures £500,000 via a Subscription of Shares,

Director's Dealing and Clinical Progress of Canine Longevity Trial

Introduction

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), is pleased to announce that it has raised gross proceeds of £500,000 (before expenses) via an allotment to Eric Leire of 62,500,000 new ordinary shares of £0.0003 each ("New Ordinary Shares") at an issue price of 0.8 pence (being the bid price as at close of business on 8 May 2025) (the "Issue Price").

The net proceeds of this fundraise will be used to advance a proof-of-concept trial evaluating the safety and efficacy of our therapeutic candidate in aged dogs, potentially being also a key translational model for age-related conditions in humans.

Issuance of the New Ordinary Shares

The Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority ("FCA") or relying upon an exemption to the requirement to issue a prospectus.

Consequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.

Following allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the "Purchaser").

Warrants

Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 1.5 pence ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.

Total Voting Rights

Application will be made for the 62,500,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the

https://www.londonstockexchange.com/news-article/GENF/share-subscription-director-s-dealing-and-update/17027661

Great news!!! Gla ;-)

Aberdeen Group, a UK-based global investment company, has taken a 2.6% position in Genflow Biosciences, indicating a significant investment. Genflow Biosciences is a longevity bioscience company focused on discovering and advancing therapeutic approaches to slow or halt aging. The investment by Aberdeen Group suggests a belief in Genflow's potential and the growing market for longevity technologies.

Key Points:

Aberdeen Group Investment:

Aberdeen Group, a FTSE 250 constituent, has invested 2.6% of Genflow Biosciences.

Genflow Biosciences:

A UK-based biotech firm with research and development in Belgium, focused on longevity and slowing down the aging process.

Investment Significance:

The investment suggests Aberdeen Group sees potential in Genflow's technology and the growing market for longevity solutions.

Genflow's Focus:

Genflow's lead compound, GF-1002, delivers a centenarian variant of the SIRT6 gene, known for promoting longevity.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,929 followers

20m

Cognitive dysfunction syndrome affects nearly 1/3 of #senior dogs, leading to confusion, #anxiety, and behavior changes. While diet and lifestyle adjustments help, #genetherapy could offer new solutions.

At Genflow Biosciences (LON:GENF) (OTCQB:GENFF), we’ve started a clinical trial in senior dogs to test the safety and possible benefits of a gene therapy designed to slow down aging. The study will measure muscle strength, muscle mass, biological age estimation (via methylation clock), and overall health indicators.

Learn more about us: https://loom.ly/uh0pGy8

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,927 followers

5h Edited

🌍 Big News for Global Longevity Science

Abu Dhabi launched the #HELM cluster - a first-of-its-kind global hub dedicated to #Health, Endurance, Longevity, and #Medicine. With its innovation friendly regulation and commitment to global #healthcare challenges, #AbuDhabi is positioning itself as a serious force in the future of #biotech.

The HELM cluster is expected to generate $25.6B in #GDP contribution and 30,000 #jobs by 2045.

A win for the global #longevity industry!

Nice one Laura, look forward to any response, in the meantime according to Eric's statement 14th October, positive data on Proof of Concept for the Dog trial could be enough to trigger a licensing deal, the PoC is expected to take 6 months and looks like it could have been iniated in January and so every chance they might be close to results by next month and so who knows, would PoC be enough for a Vet Partner to make an early move , especially if more than one is keeping an eye on proceedings!!!??? Gl :-)